{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:09:03Z","timestamp":1789380543117,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03598-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:56:08Z","timestamp":1789379768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors"],"prefix":"10.1038","author":[{"given":"Zhao","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baochun","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshuo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"3598_CR1","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41:4794\u2013820. https:\/\/doi.org\/10.1200\/JCO.23.01136.","journal-title":"J Clin Oncol"},{"key":"3598_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001.","journal-title":"Ann Oncol"},{"key":"3598_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"key":"3598_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.euf.2025.04.001","volume":"11","author":"R Barragan-Carrillo","year":"2025","unstructured":"Barragan-Carrillo R, Scavuzzo A, Jimenez-Rios MA, Sobrevilla-Moreno N. Management of metastatic renal cell carcinoma: guideline updates. Eur Urol Focus. 2025;11:436\u20139. https:\/\/doi.org\/10.1016\/j.euf.2025.04.001.","journal-title":"Eur Urol Focus"},{"key":"3598_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"key":"3598_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"3598_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033.","journal-title":"Blood"},{"key":"3598_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014.","journal-title":"Immunity"},{"key":"3598_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"3598_CR10","doi-asserted-by":"publisher","first-page":"e163447","DOI":"10.1172\/JCI163447","volume":"133","author":"VA Arrieta","year":"2023","unstructured":"Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023;133:e163447. https:\/\/doi.org\/10.1172\/JCI163447.","journal-title":"J Clin Invest"},{"key":"3598_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","volume":"42","author":"BY Nabet","year":"2024","unstructured":"Nabet BY, Hamidi H, Lee MC, Banchereau R, Morris S, Adler L, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42:429\u2013443.e4. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.010.","journal-title":"Cancer Cell"},{"key":"3598_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10:627\u201342. https:\/\/doi.org\/10.1016\/j.trecan.2024.03.008.","journal-title":"Trends Cancer"},{"key":"3598_CR13","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1360\/TB-2024-0874","volume":"70","author":"X Wang","year":"2025","unstructured":"Wang X, Yang Y, Su K, Zhao Z, Liu X, Xiong Q, et al. Immune circadian clock and tumorigenesis. Chin Sci Bull. 2025;70:3446\u201359. https:\/\/doi.org\/10.1360\/TB-2024-0874.","journal-title":"Chin Sci Bull"},{"key":"3598_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1470-2045(00)00326-0","volume":"2","author":"F L\u00e9vi","year":"2001","unstructured":"L\u00e9vi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2:307\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(00)00326-0.","journal-title":"Lancet Oncol"},{"key":"3598_CR15","doi-asserted-by":"publisher","first-page":"eabb0738","DOI":"10.1126\/science.abb0738","volume":"371","author":"A Sancar","year":"2021","unstructured":"Sancar A, Van Gelder RN. Clocks, cancer, and chronochemotherapy. Science. 2021;371:eabb0738. https:\/\/doi.org\/10.1126\/science.abb0738.","journal-title":"Science"},{"key":"3598_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-022-01238-y","volume":"15","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian rhythms and cancers: The intrinsic links and therapeutic potentials. J Hematol Oncol. 2022;15:21. https:\/\/doi.org\/10.1186\/s13045-022-01238-y.","journal-title":"J Hematol Oncol"},{"key":"3598_CR17","doi-asserted-by":"publisher","first-page":"92s","DOI":"10.1016\/j.biopha.2003.08.012","volume":"57","author":"M Eriguchi","year":"2003","unstructured":"Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. Biomed Pharmacother. 2003;57:92s\u201395s. https:\/\/doi.org\/10.1016\/j.biopha.2003.08.012. Suppl 1.","journal-title":"Biomed Pharmacother"},{"key":"3598_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nri3386","volume":"13","author":"C Scheiermann","year":"2013","unstructured":"Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol. 2013;13:190\u20138. https:\/\/doi.org\/10.1038\/nri3386.","journal-title":"Nat Rev Immunol"},{"key":"3598_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41577-018-0008-4","volume":"18","author":"C Scheiermann","year":"2018","unstructured":"Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018;18:423\u201337. https:\/\/doi.org\/10.1038\/s41577-018-0008-4.","journal-title":"Nat Rev Immunol"},{"key":"3598_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2021.07.017","volume":"126","author":"AR Damato","year":"2022","unstructured":"Damato AR, Herzog ED. Circadian clock synchrony and chronotherapy opportunities in cancer treatment. Semin Cell Dev Biol. 2022;126:27\u201336. https:\/\/doi.org\/10.1016\/j.semcdb.2021.07.017.","journal-title":"Semin Cell Dev Biol"},{"key":"3598_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/imm.13747","volume":"171","author":"J Ding","year":"2024","unstructured":"Ding J, Chen P, Qi C. Circadian rhythm regulation in the immune system. Immunology. 2024;171:525\u201333. https:\/\/doi.org\/10.1111\/imm.13747.","journal-title":"Immunology"},{"key":"3598_CR22","doi-asserted-by":"publisher","first-page":"102220","DOI":"10.1016\/j.esmoop.2023.102220","volume":"9","author":"T Landr\u00e9","year":"2024","unstructured":"Landr\u00e9 T, Karabou\u00e9 A, Buchwald ZS, Innominato PF, Qian DC, Assi\u00e9 JB, et al. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 2024;9:102220. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102220.","journal-title":"ESMO Open"},{"key":"3598_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41416-024-02704-9","volume":"131","author":"A Karabou\u00e9","year":"2024","unstructured":"Karabou\u00e9 A, Innominato PF, Wreglesworth NI, Duchemann B, Adam R, L\u00e9vi FA. Why does circadian timing of administration matter for immune checkpoint inhibitors\u2019 efficacy? Br J Cancer. 2024;131:783\u201396. https:\/\/doi.org\/10.1038\/s41416-024-02704-9.","journal-title":"Br J Cancer"},{"key":"3598_CR24","doi-asserted-by":"publisher","first-page":"e82994","DOI":"10.7759\/cureus.82994","volume":"17","author":"S Nagy","year":"2025","unstructured":"Nagy S, Hussein A, Kesselman MM. The Importance of Timing in Immunotherapy: A Systematic Review. Cureus. 2025;17:e82994. https:\/\/doi.org\/10.7759\/cureus.82994.","journal-title":"Cureus"},{"key":"3598_CR25","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1200\/jco.2022.40.16_suppl.2589","volume":"40","author":"HJ Janse van Rensburg","year":"2022","unstructured":"Janse van Rensburg HJ, Liu Z, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, et al. The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial. J Clin Oncol. 2022;40:2589. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.2589. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/hed.27825","volume":"46","author":"JR Janopaul-Naylor","year":"2024","unstructured":"Janopaul-Naylor JR, Boe L, Yu Y, Sherman EJ, Pfister DG, Lee NY, et al. Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial. Head Neck. 2024;46:2292\u20132300. https:\/\/doi.org\/10.1002\/hed.27825.","journal-title":"Head Neck"},{"key":"3598_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/imm.13897","volume":"174","author":"X Guo","year":"2025","unstructured":"Guo X, Qin L, Wang X, Geng Q, Li D, Lu Y, et al. Chronological effects of immune checkpoint inhibitors in non-small cell lung cancer. Immunology. 2025;174:402\u201310. https:\/\/doi.org\/10.1111\/imm.13897.","journal-title":"Immunology"},{"key":"3598_CR28","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2025.43.16_suppl.2662","volume":"43","author":"T Bosetti","year":"2025","unstructured":"Bosetti T, Kennedy O, Califano R, Waddell T, Serra M, Metcalf R, et al. Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: Results from a large single-centre cohort analysis. J Clin Oncol. 2025;43:2662. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2662. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3598_CR30","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815\u201334. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19981230)17:24. <2815::aid-sim110>3.0.co;2-8.","journal-title":"Stat Med"},{"key":"3598_CR31","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"3598_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","volume":"22","author":"DC Qian","year":"2021","unstructured":"Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(21)00546-5.","journal-title":"Lancet Oncol"},{"key":"3598_CR33","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.annonc.2022.07.1851","volume":"33","author":"A Cortellini","year":"2022","unstructured":"Cortellini A, Barrichello APC, Alessi JV, Ricciuti B, Vaz VR, Newsom-Davis T, et al. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions. Ann Oncol. 2022;33:1202\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1851. (letter).","journal-title":"Ann Oncol"},{"key":"3598_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/cancers14040896","volume":"14","author":"A Karabou\u00e9","year":"2022","unstructured":"Karabou\u00e9 A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers. 2022;14:896. https:\/\/doi.org\/10.3390\/cancers14040896.","journal-title":"Cancers"},{"key":"3598_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clgc.2023.06.004","volume":"21","author":"N Dizman","year":"2023","unstructured":"Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, et al. Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2023;21:530\u20136. https:\/\/doi.org\/10.1016\/j.clgc.2023.06.004.","journal-title":"Clin Genitourin Cancer"},{"key":"3598_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10388-023-01006-y","volume":"20","author":"M Nomura","year":"2023","unstructured":"Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus. 2023;20:722\u201331. https:\/\/doi.org\/10.1007\/s10388-023-01006-y.","journal-title":"Esophagus"},{"key":"3598_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2023.01.007","volume":"182","author":"A Rousseau","year":"2023","unstructured":"Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A, et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023;182:107\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.007.","journal-title":"Eur J Cancer"},{"key":"3598_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/imt-2022-0139","volume":"15","author":"C Yeung","year":"2023","unstructured":"Yeung C, Kartolo A, Tong J, Hopman W, Baetz T. Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma. Immunotherapy. 2023;15:819\u201326. https:\/\/doi.org\/10.2217\/imt-2022-0139.","journal-title":"Immunotherapy"},{"key":"3598_CR39","doi-asserted-by":"publisher","first-page":"113571","DOI":"10.1016\/j.ejca.2024.113571","volume":"199","author":"S Catozzi","year":"2024","unstructured":"Catozzi S, Assaad S, Delrieu L, Favier B, Dumas E, Hamy A-S, et al. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. Eur J Cancer. 2024;199:113571. https:\/\/doi.org\/10.1016\/j.ejca.2024.113571.","journal-title":"Eur J Cancer"},{"key":"3598_CR40","doi-asserted-by":"publisher","first-page":"e008011","DOI":"10.1136\/jitc-2023-008011","volume":"12","author":"JS Patel","year":"2024","unstructured":"Patel JS, Woo Y, Draper A, Jansen CS, Carlisle JW, Innominato PF, et al. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J Immunother Cancer. 2024;12:e008011. https:\/\/doi.org\/10.1136\/jitc-2023-008011.","journal-title":"J Immunother Cancer"},{"key":"3598_CR41","doi-asserted-by":"publisher","first-page":"106761","DOI":"10.1016\/j.oraloncology.2024.106761","volume":"151","author":"DA Ruiz-Torres","year":"2024","unstructured":"Ruiz-Torres DA, Naegele S, Podury A, Wirth L, Shalhout SZ, Faden DL. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral Oncol. 2024;151:106761. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106761.","journal-title":"Oral Oncol"},{"key":"3598_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3892\/ol.2024.14596","volume":"28","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Suzuki H, Yamaguchi S, Shimotsuura Y, Nagasu S, Murotani K, et al. Efficacy of timing\u2011dependent infusion of nivolumab in patients with advanced gastric cancer. Oncol Lett. 2024;28:463. https:\/\/doi.org\/10.3892\/ol.2024.14596.","journal-title":"Oncol Lett"},{"key":"3598_CR43","doi-asserted-by":"publisher","first-page":"1512972","DOI":"10.3389\/fimmu.2024.1512972","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Shi F, Sun L, Guo J, Ren T, Ma J. Effect of immune checkpoint inhibitor time-of-day infusion on survival in advanced biliary tract cancer: a propensity score-matched analysis. Front Immunol. 2024;15:1512972. https:\/\/doi.org\/10.3389\/fimmu.2024.1512972.","journal-title":"Front Immunol"},{"key":"3598_CR44","doi-asserted-by":"publisher","first-page":"103371","DOI":"10.1016\/j.annder.2025.103371","volume":"152","author":"M Amici","year":"2025","unstructured":"Amici M, Neveu E, Poizeau F, Edeline J, Lesimple T, Oger E, et al. The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study. Ann Dermatol Venereol. 2025;152:103371. https:\/\/doi.org\/10.1016\/j.annder.2025.103371.","journal-title":"Ann Dermatol Venereol"},{"key":"3598_CR45","doi-asserted-by":"publisher","first-page":"1653218","DOI":"10.3389\/fimmu.2025.1653218","volume":"16","author":"C Cheng","year":"2025","unstructured":"Cheng C, Cheng X, Wang T. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis. Front Immunol. 2025;16:1653218. https:\/\/doi.org\/10.3389\/fimmu.2025.1653218.","journal-title":"Front Immunol"},{"key":"3598_CR46","doi-asserted-by":"publisher","first-page":"e950963","DOI":"10.12659\/MSM.950963","volume":"31","author":"M Ersoy","year":"2025","unstructured":"Ersoy M. Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer. Med Sci Monit. 2025;31:e950963. https:\/\/doi.org\/10.12659\/MSM.950963.","journal-title":"Med Sci Monit"},{"key":"3598_CR47","doi-asserted-by":"publisher","first-page":"976","DOI":"10.21873\/invivo.13903","volume":"39","author":"N Furubayashi","year":"2025","unstructured":"Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T. Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing. Vivo. 2025;39:976\u201387. https:\/\/doi.org\/10.21873\/invivo.13903.","journal-title":"Vivo"},{"key":"3598_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21037\/tlcr-24-571","volume":"14","author":"I Gomez-Randulfe","year":"2025","unstructured":"Gomez-Randulfe I, Pearce M, Netto D, Ward R, Califano R. Association between immunotherapy timing and efficacy in non-small cell lung cancer: a comprehensive analysis at a high-volume specialist centre. Transl Lung Cancer Res. 2025;14:72\u201380. https:\/\/doi.org\/10.21037\/tlcr-24-571.","journal-title":"Transl Lung Cancer Res"},{"key":"3598_CR49","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cancers17050898","volume":"17","author":"L Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves L, Guedes H, Fortuna AR, Lemos T, Grama\u00e7a J, Mour\u00e3o N, et al. Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing. Cancers. 2025;17:898. https:\/\/doi.org\/10.3390\/cancers17050898.","journal-title":"Cancers"},{"key":"3598_CR50","doi-asserted-by":"publisher","first-page":"105607","DOI":"10.1016\/j.ebiom.2025.105607","volume":"113","author":"Z Huang","year":"2025","unstructured":"Huang Z, Karabou\u00e9 A, Zeng L, Lecoeuvre A, Zhang L, Li X-M, et al. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study. eBioMedicine. 2025;113:105607. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105607.","journal-title":"eBioMedicine"},{"key":"3598_CR51","doi-asserted-by":"publisher","first-page":"e70126","DOI":"10.1002\/cncr.70126","volume":"131","author":"Z Huang","year":"2025","unstructured":"Huang Z, Ruan Z, Xu S, Zou N, Deng L, Yan H, et al. Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer. Cancer. 2025;131:e70126. https:\/\/doi.org\/10.1002\/cncr.70126.","journal-title":"Cancer"},{"key":"3598_CR52","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.21873\/anticanres.17848","volume":"45","author":"Y Iwahashi","year":"2025","unstructured":"Iwahashi Y, Tamiya A, Tanaka T, Tamiya M, Tsukaguchi A, Inagaki Y, et al. Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment. Anticancer Res. 2025;45:5077\u201384. https:\/\/doi.org\/10.21873\/anticanres.17848.","journal-title":"Anticancer Res"},{"key":"3598_CR53","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/hepr.14171","volume":"55","author":"A Naganuma","year":"2025","unstructured":"Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, et al. Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. Hepatol Res. 2025;55:741\u201351. https:\/\/doi.org\/10.1111\/hepr.14171.","journal-title":"Hepatol Res"},{"key":"3598_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/jcm15010069","volume":"15","author":"A Nepote","year":"2026","unstructured":"Nepote A, Burghgraeve G, Pedrani M, Gomez Ramos AJ, Saporita I, Spataro V, et al. ChronoimmunoTOX: a single-institution retrospective study on how the time of administration impacts immune checkpoint inhibitor efficacy and toxicity in melanoma. J Clin Med. 2026;15:69. https:\/\/doi.org\/10.3390\/jcm15010069.","journal-title":"J Clin Med"},{"key":"3598_CR55","doi-asserted-by":"publisher","first-page":"115748","DOI":"10.1016\/j.ejca.2025.115748","volume":"228","author":"A Tsukaguchi","year":"2025","unstructured":"Tsukaguchi A, Matsumoto K, Tamiya A, Tamiya M, Mori M, Suzuki H, et al. Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: a retrospective multicenter study. Eur J Cancer. 2025;228:115748. https:\/\/doi.org\/10.1016\/j.ejca.2025.115748.","journal-title":"Eur J Cancer"},{"key":"3598_CR56","doi-asserted-by":"publisher","first-page":"107772","DOI":"10.1016\/j.oraloncology.2025.107772","volume":"171","author":"P Van Loocke","year":"2025","unstructured":"Van Loocke P, Beuselinck B, Meulemans J, Nuyts S, Willaert R, Di Santo D, et al. Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent\/metastatic head and neck cancer (R\/M HNSCC): a retrospective cohort study. Oral Oncol. 2025;171:107772. https:\/\/doi.org\/10.1016\/j.oraloncology.2025.107772.","journal-title":"Oral Oncol"},{"key":"3598_CR57","doi-asserted-by":"publisher","first-page":"175883592513399","DOI":"10.1177\/17588359251339921","volume":"17","author":"Y Ishizuka","year":"2025","unstructured":"Ishizuka Y, Narita Y, Sakakida T, Wakabayashi M, Kodama H, Honda K, et al. Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer. Ther Adv Med Oncol. 2025;17:17588359251339921. https:\/\/doi.org\/10.1177\/17588359251339921.","journal-title":"Ther Adv Med Oncol"},{"key":"3598_CR58","doi-asserted-by":"publisher","first-page":"S835","DOI":"10.1016\/j.annonc.2021.08.1352","volume":"32","author":"A Vilalta","year":"2021","unstructured":"Vilalta A, Arasanz H, Rodriguez-Remirez M, Lopez I, Puyalto A, Lecumberri A, et al. 967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer. Ann Oncol. 2021;32:S835. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1352. (abstract).","journal-title":"Ann Oncol"},{"key":"3598_CR59","doi-asserted-by":"publisher","first-page":"e16541","DOI":"10.1200\/jco.2022.40.16_suppl.e16541","volume":"40","author":"I Ortego","year":"2022","unstructured":"Ortego I, Molina-Cerrillo J, Pinto A, Santoni M, Alonso-Gordoa T, Lopez Criado MP, et al. Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes? J Clin Oncol. 2022;40:e16541. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e16541. (abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR60","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/jco.2023.41.6_suppl.681","volume":"41","author":"L Fernandez-Ma\u00f1as","year":"2023","unstructured":"Fernandez-Ma\u00f1as L, Gonzalez Aguado L, Aversa C, Ferrer-Mileo L, Garcia De Herreros M, Jim\u00e9nez N, et al. Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study. J Clin Oncol. 2023;41:681. https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.681. (Suppl 6)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR61","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.iotech.2023.100554","volume":"20","author":"MI Gomez-Randulfe Rodriguez","year":"2023","unstructured":"Gomez-Randulfe Rodriguez MI, Pearce M, Gomes F, Lindsay C, Summers Y, Blackhall F, et al. 82\u2009P the role of circadian rhythms in NSCLC immunotherapy efficacy: a focus on first dose timing. Immuno-Oncol Technol. 2023;20:100554. https:\/\/doi.org\/10.1016\/j.iotech.2023.100554. (abstract).","journal-title":"Immuno-Oncol Technol"},{"key":"3598_CR62","doi-asserted-by":"publisher","first-page":"e21055","DOI":"10.1200\/jco.2023.41.16_suppl.e21055","volume":"41","author":"A Karabou\u00e9","year":"2023","unstructured":"Karabou\u00e9 A, Collon T, Innominato P, Chouahnia K, Adam R, Levi F. Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer. J Clin Oncol. 2023;41:e21055. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.e21055. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR63","doi-asserted-by":"publisher","first-page":"e16537","DOI":"10.1200\/jco.2024.42.16_suppl.e16537","volume":"42","author":"AM Arroyave Ramirez","year":"2024","unstructured":"Arroyave Ramirez AM, Motola D, Morales Garcia MG, Conde-Flores E. Impact of time-of-day administration of immunotherapy on overall survival among patients with metastatic renal cell carcinoma. J Clin Oncol. 2024;42:e16537. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e16537. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR64","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1200\/jco.2024.42.16_suppl.9542","volume":"42","author":"L Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves L, Goncalves D, Casanelles TE, Guerra LP, Menezes MB, Duarte Branco V, et al. Retro TIMing: a multicentric retrospective analysis of immunotherapy timing in metastatic melanoma. J Clin Oncol. 2024;42:9542. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.9542. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/jco.2024.42.3_suppl.457","volume":"42","author":"A Pascale","year":"2024","unstructured":"Pascale A, Allard MA, Benamar A, Levi F, Adam R, Rosmorduc O. Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2024;42:457. https:\/\/doi.org\/10.1200\/jco.2024.42.3_suppl.457. (Suppl 3)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR66","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1016\/j.jtho.2024.09.1127","volume":"19","author":"R Tagawa","year":"2024","unstructured":"Tagawa R, Takemoto S, Gyotoku H, Taniguchi H, Matsuo M, Tomono H, et al. EP.11A.16 infusion timing of ICI monotherapy in patients with advanced NSCLC: a single institution-retrospective study. J Thorac Oncol. 2024;19:S602\u2013S603. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1127. (abstract).","journal-title":"J Thorac Oncol"},{"key":"3598_CR67","doi-asserted-by":"publisher","first-page":"S1558","DOI":"10.1016\/j.annonc.2024.10.436","volume":"35","author":"T Tsunoki","year":"2024","unstructured":"Tsunoki T, Kadowaki S, Mizuno T, Ishizuka Y, Sakakida T, Narita Y, et al. 413MO Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma. Ann Oncol. 2024;35:S1558. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.436. (abstract).","journal-title":"Ann Oncol"},{"key":"3598_CR68","doi-asserted-by":"publisher","first-page":"S1712","DOI":"10.1016\/j.annonc.2025.08.229","volume":"36","author":"Y Oya","year":"2025","unstructured":"Oya Y. MO47-1 Early administration of immune checkpoint inhibitors \u00b1 chemotherapy affects efficacy in patients with advanced NSCLC. Ann Oncol. 2025;36:S1712. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.229. (abstract).","journal-title":"Ann Oncol"},{"key":"3598_CR69","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.iotech.2025.101242","volume":"28","author":"S Schultz","year":"2025","unstructured":"Schultz S, Mohr R, Knott A, Amundson B, King E, Chittavong V, et al. 159P Impact of initial timing of immune checkpoint inhibitor administration on outcomes in metastatic non-small cell lung cancer. Immuno-Oncol Technol. 2025;28:101242. https:\/\/doi.org\/10.1016\/j.iotech.2025.101242. (abstract).","journal-title":"Immuno-Oncol Technol"},{"key":"3598_CR70","doi-asserted-by":"publisher","first-page":"106958","DOI":"10.1016\/j.esmoop.2026.106958","volume":"11","author":"S Peters","year":"2026","unstructured":"Peters S, Dafni U, Federer-Gsponer J, Ballinger M, Christopeit M, Dimopoulou G, et al. LBA2 ETOP-Roche i-TIMES: Immunotherapy timing investigation on lung cancer survival. ESMO Open. 2026;11:106958. https:\/\/doi.org\/10.1016\/j.esmoop.2026.106958. (abstract).","journal-title":"ESMO Open"},{"key":"3598_CR71","doi-asserted-by":"publisher","first-page":"e21126","DOI":"10.1200\/jco.2022.40.16_suppl.e21126","volume":"40","author":"CH Barrios","year":"2022","unstructured":"Barrios CH, Montella TC, Ferreira CGM, De Marchi P, Coutinho LF, Lemos Duarte I, et al. Time-of-day infusion of immunotherapy may impact outcomes in advanced non-small cell lung cancer patients (NSCLC). J Clin Oncol. 2022;40:e21126. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e21126.","journal-title":"J Clin Oncol"},{"key":"3598_CR72","doi-asserted-by":"publisher","first-page":"e16512","DOI":"10.1200\/jco.2022.40.16_suppl.e16512","volume":"40","author":"J Molina-Cerrillo","year":"2022","unstructured":"Molina-Cerrillo J, Ortego I, Pinto A, Alonso-Gordoa T, Massari F, Aurilio G, et al. Does timing of immune checkpoint inhibitors (ICIs) administration in first line metastatic renal cell carcinoma (mRCC) have impact in survival outcomes? J Clin Oncol. 2022;40:e16512. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e16512. (Suppl 16)(abstract).","journal-title":"J Clin Oncol"},{"key":"3598_CR73","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/cancers17050732","volume":"17","author":"RM Fey","year":"2025","unstructured":"Fey RM, Billo A, Clister T, Doan KL, Berry EG, Tibbitts DC, et al. Personalization of cancer treatment: exploring the role of chronotherapy in immune checkpoint inhibitor efficacy. Cancers. 2025;17:732. https:\/\/doi.org\/10.3390\/cancers17050732.","journal-title":"Cancers"},{"key":"3598_CR74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4103\/ijmpo.ijmpo_193_16","volume":"38","author":"PB Chaudhari","year":"2017","unstructured":"Chaudhari PB. Nivolumab\u2013pearls of evidence. Indian J Med Paediatr Oncol. 2017;38:520\u20135. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_193_16.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"3598_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.immuni.2016.12.011","volume":"46","author":"D Druzd","year":"2017","unstructured":"Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, et al. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity. 2017;46:120\u201332. https:\/\/doi.org\/10.1016\/j.immuni.2016.12.011.","journal-title":"Immunity"},{"key":"3598_CR76","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.tcb.2021.06.008","volume":"31","author":"W Xuan","year":"2021","unstructured":"Xuan W, Khan F, James CD, Heimberger AB, Lesniak MS, Chen P. Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends Cell Biol. 2021;31:940\u201350. https:\/\/doi.org\/10.1016\/j.tcb.2021.06.008.","journal-title":"Trends Cell Biol"},{"key":"3598_CR77","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","volume":"614","author":"C Wang","year":"2023","unstructured":"Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, et al. Dendritic cells direct circadian anti-tumour immune responses. Nature. 2023;614:136\u201343. https:\/\/doi.org\/10.1038\/s41586-022-05605-0.","journal-title":"Nature"},{"key":"3598_CR78","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1541-7786.MCR-21-0786","volume":"20","author":"A Tsuruta","year":"2022","unstructured":"Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S, et al. Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1\/PD-L1 inhibitor BMS-1 in B16\/BL6 melanoma-bearing mice. Mol Cancer Res. 2022;20:972\u201382. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0786.","journal-title":"Mol Cancer Res"},{"key":"3598_CR79","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","volume":"25","author":"BM Fortin","year":"2024","unstructured":"Fortin BM, Pfeiffer SM, Insua-Rodr\u00edguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:1257\u201369. https:\/\/doi.org\/10.1038\/s41590-024-01859-0.","journal-title":"Nat Immunol"},{"key":"3598_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.irn.2016.07.002","volume":"131","author":"RM Voigt","year":"2016","unstructured":"Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian rhythm and the gut microbiome. Int Rev Neurobiol. 2016;131:193\u2013205. https:\/\/doi.org\/10.1016\/bs.irn.2016.07.002.","journal-title":"Int Rev Neurobiol"},{"key":"3598_CR81","doi-asserted-by":"publisher","first-page":"e202895","DOI":"10.1001\/jamanetworkopen.2020.2895","volume":"3","author":"M Nomura","year":"2020","unstructured":"Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open. 2020;3:e202895. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2895.","journal-title":"JAMA Netw Open"},{"key":"3598_CR82","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835\u201357. https:\/\/doi.org\/10.1007\/s40262-019-00748-2.","journal-title":"Clin Pharmacokinet"},{"key":"3598_CR83","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"F L\u00e9vi","year":"2010","unstructured":"L\u00e9vi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharm Toxicol. 2010;50:377\u2013421. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094626.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"3598_CR84","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0006-3223(03)00566-3","volume":"54","author":"D Spiegel","year":"2003","unstructured":"Spiegel D, Giese-Davis J. Depression and cancer: Mechanisms and disease progression. Biol Psychiatry. 2003;54:269\u201382. https:\/\/doi.org\/10.1016\/s0006-3223(03)00566-3.","journal-title":"Biol Psychiatry"},{"key":"3598_CR85","doi-asserted-by":"publisher","first-page":"12843","DOI":"10.1073\/pnas.0701466104","volume":"104","author":"G Cavadini","year":"2007","unstructured":"Cavadini G, Petrzilka S, Kohler P, Jud C, Tobler I, Birchler T, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA. 2007;104:12843\u20138. https:\/\/doi.org\/10.1073\/pnas.0701466104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3598_CR86","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2019.07.002","volume":"5","author":"G Sulli","year":"2019","unstructured":"Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: New frontiers for cancer treatment. Trends Cancer. 2019;5:475\u201394. https:\/\/doi.org\/10.1016\/j.trecan.2019.07.002.","journal-title":"Trends Cancer"},{"key":"3598_CR87","first-page":"3038","volume":"6","author":"MC Mormont","year":"2000","unstructured":"Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest\/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038\u201345.","journal-title":"Clin Cancer Res"},{"key":"3598_CR88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-051920-095416","volume":"64","author":"FA L\u00e9vi","year":"2024","unstructured":"L\u00e9vi FA, Okyar A, Hadadi E, Innominato PF, Ballesta A. Circadian regulation of drug responses: toward sex-specific and personalized chronotherapy. Annu Rev Pharm Toxicol. 2024;64:89\u2013114. https:\/\/doi.org\/10.1146\/annurev-pharmtox-051920-095416.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"3598_CR89","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17:233\u201347. https:\/\/doi.org\/10.1038\/nri.2017.1.","journal-title":"Nat Rev Immunol"},{"key":"3598_CR90","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90.","journal-title":"Nat Rev Immunol"},{"key":"3598_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/074873099129000641","volume":"14","author":"AJ Lewy","year":"1999","unstructured":"Lewy AJ, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms. 1999;14:227\u201336. https:\/\/doi.org\/10.1177\/074873099129000641.","journal-title":"J Biol Rhythms"},{"key":"3598_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1131","volume":"12","author":"EB Klerman","year":"2022","unstructured":"Klerman EB, Brager A, Carskadon MA, Depner CM, Foster R, Goel N, et al. Keeping an eye on circadian time in clinical research and medicine. Clin Transl Med. 2022;12:e1131. https:\/\/doi.org\/10.1002\/ctm2.1131.","journal-title":"Clin Transl Med"},{"key":"3598_CR93","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1172\/JCI120874","volume":"128","author":"N Wittenbrink","year":"2018","unstructured":"Wittenbrink N, Ananthasubramaniam B, M\u00fcnch M, Koller B, Maier B, Weschke C, et al. High-accuracy determination of internal circadian time from a single blood sample. J Clin Invest. 2018;128:3826\u201339. https:\/\/doi.org\/10.1172\/JCI120874.","journal-title":"J Clin Invest"},{"key":"3598_CR94","doi-asserted-by":"publisher","first-page":"zsz254","DOI":"10.1093\/sleep\/zsz254","volume":"43","author":"CM Depner","year":"2020","unstructured":"Depner CM, Cheng PC, Devine JK, Khosla S, de Zambotti M, Robillard R, et al. Wearable technologies for developing sleep and circadian biomarkers: A summary of workshop discussions. Sleep. 2020;43:zsz254. https:\/\/doi.org\/10.1093\/sleep\/zsz254.","journal-title":"Sleep"},{"key":"3598_CR95","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jsmc.2009.01.004","volume":"4","author":"JF Duffy","year":"2009","unstructured":"Duffy JF, Czeisler CA. Effect of light on human circadian physiology. Sleep Med Clin. 2009;4:165\u201377. https:\/\/doi.org\/10.1016\/j.jsmc.2009.01.004.","journal-title":"Sleep Med Clin"},{"key":"3598_CR96","doi-asserted-by":"publisher","first-page":"1428601","DOI":"10.3389\/fphar.2024.1428601","volume":"15","author":"A Ribas-Latre","year":"2024","unstructured":"Ribas-Latre A, Fern\u00e1ndez-Veledo S, Vendrell J. Time-restricted eating, the clock ticking behind the scenes. Front Pharm. 2024;15:1428601. https:\/\/doi.org\/10.3389\/fphar.2024.1428601.","journal-title":"Front Pharm"},{"key":"3598_CR97","doi-asserted-by":"publisher","first-page":"104632","DOI":"10.1016\/j.critrevonc.2025.104632","volume":"208","author":"O Ogunlusi","year":"2025","unstructured":"Ogunlusi O, Ghosh A, Sarkar M, Carter K, Davuluri H, Chakraborty M, et al. Rhythm is essential: unraveling the relation between the circadian clock and cancer. Crit Rev Oncol Hematol. 2025;208:104632. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104632.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3598_CR98","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41591-025-04181-w","volume":"32","author":"Z Huang","year":"2026","unstructured":"Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, et al. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026;32:1233\u201340. https:\/\/doi.org\/10.1038\/s41591-025-04181-w.","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03598-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:56:10Z","timestamp":1789379770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03598-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":98,"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03598-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published data and does not involve human participants or animal experiments.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}